© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 21, 1748-1751,
November 3, 1993
© 1993 Oxford University Press
Elevation of Multiple Serum Markers in Patients With Stage I Ovarian Cancer
R. P. Woolas, I. J. Jacobs, D. H. Oram, The Royal London Hospital, Cambridge University London, England
Duke University Medical Center Durham, N.C.
Correspondence to: Robert C. Bast, Jr., M.D., Box 3843, Duke University Medical Center, Durham, NC 27710.
BACKGROUND: The high overall mortality from ovarian cancer (>60%) relates, in part, to delays in diagnosis. When ovarian cancer is detected in stage I (International Federation of Gynecology and Obstetrics staging), up to 90% of patients can be cured. Transvaginal sonography can detect early-stage disease with great sensitivity, but it is expensive and lacks specificity. Although serum marker assays could provide a less expensive and more convenient initial screening test, the sensitivity of assays varies. Measurement of serum CA 125 in conjunction with ultrasound screening as a second-line test confers high specificity but detects only about one half of early stage ovarian carcinomas.
PURPOSE: The purpose of this retrospective study was to determine whether assays of multiple serum markers would improve sensitivity by detecting a higher percentage of stage I ovarian cancers than the CA 125 assay alone.
METHODS: Using immu-noradiometric assays, we measured preoperative serum levels of CA 125 tumor-associated antigen, mac-rophage colony-stimulating factor (M-CSF), and OVX1 in 46 patients with stage I ovarian cancer of different histologies and 237 patients with benign pelvic masses. We also assayed sera from 204 apparently healthy women who had participated in a screening trial and remained free from cancer at 1 year of follow-up. All specimens were obtained from cryopreserved aliquots. Marker levels were considered to be elevated when levels of CA 125 were greater than 30 U/mL, M-CSF levels were greater than 3.1 ng/mL, or OVX1 levels were greater than 12.1 U/mL.
RESULTS: At least one of the serum markers was elevated in 98% of patients with stage I ovarian cancer; CA 125 levels were elevated in 67%. By the same criteria, 11% of healthy individuals and 51% of patients with benign pelvic masses had at least one elevated marker value. Thus, the sensitivity of the combination of assays for the three serum markers was significantly greater than the sensitivity of the CA 125 assay (P<.0005) and specificity was moderate.
CONCLUSIONS: A panel of these three tumor markers can identify early-stage ovarian cancer with extremely high sensitivity and moderate specificity.
IMPLICATIONS: Elevation of one or more serum markers should be evaluated further as an Indication for transvaginal sonogra-phy in apparently healthy women. Such a strategy might substantially reduce the expense and improve the specificity of screening compared to the use of ultrasound alone. Prospective studies with a large cohort of patients at high risk for ovarian cancer will be required to confirm these findings. [J Natl Cancer Inst 85:1748–1751, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. L. Clarke-Pearson Screening for Ovarian Cancer N. Engl. J. Med., July 9, 2009; 361(2): 170 - 177. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Koomen, E. B. Haura, G. Bepler, R. Sutphen, E. R. Remily-Wood, K. Benson, M. Hussein, L. A. Hazlehurst, T. J. Yeatman, L. T. Hildreth, et al. Proteomic Contributions to Personalized Cancer Care Mol. Cell. Proteomics, October 1, 2008; 7(10): 1780 - 1794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Henic, C. Borgfeldt, I. J. Christensen, B. Casslen, and G. Hoyer-Hansen Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5785 - 5793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. C. Shan, A. Scorilas, D. Katsaros, I. Rigault de la Longrais, M. Massobrio, and E. P. Diamandis Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer Cytosols Clin. Chem., October 1, 2006; 52(10): 1879 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mor, I. Visintin, Y. Lai, H. Zhao, P. Schwartz, T. Rutherford, L. Yue, P. Bray-Ward, and D. C. Ward Serum protein markers for early detection of ovarian cancer PNAS, May 24, 2005; 102(21): 7677 - 7682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Baron, C. H. Boardman, J. M. Lafky, A. Rademaker, D. Liu, D. A. Fishman, K. C. Podratz, and N. J. Maihle Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 306 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Skates, N. Horick, Y. Yu, F.-J. Xu, A. Berchuck, L. J. Havrilesky, H. W.A. de Bruijn, A. G.J. van der Zee, R. P. Woolas, I. J. Jacobs, et al. Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions J. Clin. Oncol., October 15, 2004; 22(20): 4059 - 4066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Jacobs and U. Menon Progress and Challenges in Screening for Early Detection of Ovarian Cancer Mol. Cell. Proteomics, April 1, 2004; 3(4): 355 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Yousef, A. Scorilas, D. Katsaros, S. Fracchioli, L. Iskander, C. Borgono, I. A. Rigault de la Longrais, M. Puopolo, M. Massobrio, and E. P. Diamandis Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer J. Clin. Oncol., August 15, 2003; 21(16): 3119 - 3126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Bast Jr Status of Tumor Markers in Ovarian Cancer Screening J. Clin. Oncol., May 15, 2003; 21(90100): 200s - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis, A. Scorilas, S. Fracchioli, M. van Gramberen, H. de Bruijn, A. Henrik, A. Soosaipillai, L. Grass, G. M. Yousef, U.-H. Stenman, et al. Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma J. Clin. Oncol., March 15, 2003; 21(6): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A secondary interpretation is needed on serum CA 125 levels in case of serosal involvement Perspectives in Public Health, December 1, 2000; 120(4): 268 - 270. [PDF]
|
|
|
|
 |
|
 J. Gong, N. Nikrui, D. Chen, S. Koido, Z. Wu, Y. Tanaka, S. Cannistra, D. Avigan, and D. Kufe Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity J. Immunol., August 1, 2000; 165(3): 1705 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V.S. Hogdall, C. K. Hogdall, S. K. Kjaer, F. Xu, Y. Yu, R. C. Bast, J. Blaakaer, and I. J. Jacobs OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage Clin. Chem., May 1, 1999; 45(5): 692 - 694. [Full Text] [PDF]
|
|
|
|
 |
|
 H. T. Lynch, M. J. Casey, T. G. Shaw, and J. F. Lynch Hereditary Factors in Gynecologic Cancer Oncologist, October 1, 1998; 3(5): 319 - 338. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Xu, Z. Shen, D. W. Wiper, M. Wu, R. E. Morton, P. Elson, A. W. Kennedy, J. Belinson, M. Markman, and G. Casey Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers JAMA, August 26, 1998; 280(8): 719 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Roberts Searching for a Biomarker for Ovarian Cancer JAMA, August 26, 1998; 280(8): 739 - 739. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Fritsche and R. C. Bast CA 125 in Ovarian Cancer: Advances and Controversy Clin. Chem., July 1, 1998; 44(7): 1379 - 1380. [Full Text] [PDF]
|
|
|
|
|
|
K. Eagle and J. A. Ledermann Tumor Markers in Ovarian Malignancies Oncologist, October 1, 1997; 2(5): 324 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J Jacobs, S. Skates, A. P. Davies, R. P Woolas, A. Jeyerajah, P. Weidemann, K. Sibley, and D. H Oram Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study BMJ, November 30, 1996; 313(7069): 1355 - 1358. [Abstract] [Full Text]
|
|